New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

Cambridge, USA-based mRNA vaccines company Moderna today announced the expansion of its US manufacturing capabilities with ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

Moderna is investing more than $140 million to bring drug manufacturing to its Massachusetts campus, a move that it says will ...

A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S.

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...